Last reviewed · How we verify
RIG-C
At a glance
| Generic name | RIG-C |
|---|---|
| Also known as | Rabies Immune Globulin (Human), Caprylate/Chromatography Purified |
| Sponsor | Grifols Therapeutics LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma (PHASE1, PHASE2)
- An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RIG-C CI brief — competitive landscape report
- RIG-C updates RSS · CI watch RSS
- Grifols Therapeutics LLC portfolio CI